GILD logo Gilead Sciences +
Gilead Sciences
+

Gilead Sciences (GILD) Business News

Track Gilead Sciences in real time with a live news feed covering Gilead Sciences stock news, official press releases, company announcements, and an archive of historical Gilead Sciences news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection
9:21 PM | Thursday | May 14, 2026 Business Wire

Gilead Prices $3 Billion of Senior Unsecured Notes

News Thumbnail
10:30 AM | Wednesday | May 13, 2026 Zacks Investment Research

Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?

News Thumbnail
9:15 AM | Wednesday | May 13, 2026 Seeking Alpha

Gilead's Transition Into A Long-Duration Biotech Platform

News Thumbnail
8:30 AM | Wednesday | May 13, 2026 Business Wire

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

News Thumbnail
10:30 AM | Wednesday | May 13, 2026 Zacks Investment Research

Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?

News Thumbnail
9:15 AM | Wednesday | May 13, 2026 Seeking Alpha

Gilead's Transition Into A Long-Duration Biotech Platform

News Thumbnail
8:30 AM | Wednesday | May 13, 2026 Business Wire

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

News Thumbnail
8:00 PM | Tuesday | May 12, 2026 Seeking Alpha

Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

News Thumbnail
12:26 PM | Friday | May 8, 2026 Zacks Investment Research

GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View

News Thumbnail
1:01 AM | Friday | May 8, 2026 Seeking Alpha

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

News Thumbnail
7:01 PM | Thursday | May 7, 2026 Zacks Investment Research

Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

News Thumbnail
6:16 PM | Thursday | May 7, 2026 Zacks Investment Research

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

News Thumbnail
4:39 PM | Thursday | May 7, 2026 WSJ

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

News Thumbnail
4:05 PM | Thursday | May 7, 2026 Reuters

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

News Thumbnail

Gilead Prices $3 Billion of Senior Unsecured Notes

Business Wire

9:21 PM | Thursday | May 14, 2026

news photo
Loading...

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.
600% senior notes maturi.

Read full article redirect
9:21 PM | Thursday | May 14, 2026

Gilead Prices $3 Billion of Senior Unsecured Notes

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD), a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, today announced the pricing of senior unsecured notes in an aggregate principal amount of $3 billion, in an underwritten, registered public offering, consisting of $500 million of 4.250% senior notes maturing in 2028, $1 billion of 4.400% senior notes maturing in 2029, $1 billion of 4.
600% senior notes maturi.

Read full article arrow
News Thumbnail
10:30 AM | Wednesday | May 13, 2026

Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?

Zacks Investment Research

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Read full article arrow
News Thumbnail
9:15 AM | Wednesday | May 13, 2026

Gilead's Transition Into A Long-Duration Biotech Platform

Seeking Alpha

Gilead Sciences is executing a successful transition from a mature antiviral company to a diversified therapeutic platform, driving a 34% stock rally. HIV revenue grew 10% YoY, with Yeztugo's explosive PrEP growth and raised guidance to $1B, signaling a durable, long-acting franchise. Oncology is gaining strategic coherence, led by Trodelvy's 37% YoY growth and platform expansion via acquisitions in ADCs, CAR-T, and autoimmune.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | May 13, 2026

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study data for Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union.
Analyses fr.

Read full article arrow
News Thumbnail
10:30 AM | Wednesday | May 13, 2026

Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views?

Zacks Investment Research

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Read full article arrow
News Thumbnail
9:15 AM | Wednesday | May 13, 2026

Gilead's Transition Into A Long-Duration Biotech Platform

Seeking Alpha

Gilead Sciences is executing a successful transition from a mature antiviral company to a diversified therapeutic platform, driving a 34% stock rally. HIV revenue grew 10% YoY, with Yeztugo's explosive PrEP growth and raised guidance to $1B, signaling a durable, long-acting franchise. Oncology is gaining strategic coherence, led by Trodelvy's 37% YoY growth and platform expansion via acquisitions in ADCs, CAR-T, and autoimmune.

Read full article arrow
News Thumbnail
8:30 AM | Wednesday | May 13, 2026

Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) will present findings from 29 abstracts, including late-breaking presentations at the European Association for the Study of the Liver (EASL) Congress, May 27-30, 2026, Barcelona. These presentations advance understanding of primary biliary cholangitis (PBC) and viral hepatitis. In PBC, Gilead will present randomized and long-term study data for Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union.
Analyses fr.

Read full article arrow
News Thumbnail
8:00 PM | Tuesday | May 12, 2026

Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha

Gilead Sciences, Inc. (GILD) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Read full article arrow
News Thumbnail
12:26 PM | Friday | May 8, 2026

GILD Beats Q1 Earnings and Sales Estimates, Lowers '26 EPS View

Zacks Investment Research

GILD beats Q1 estimates as HIV and Trodelvy sales rise, but shares slip after the company cuts its 2026 EPS outlook.

Read full article arrow
News Thumbnail
1:01 AM | Friday | May 8, 2026

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

Seeking Alpha

Gilead Sciences, Inc. (GILD) Q1 2026 Earnings Call Transcript

Read full article arrow
News Thumbnail
7:01 PM | Thursday | May 7, 2026

Gilead (GILD) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read full article arrow
News Thumbnail
6:16 PM | Thursday | May 7, 2026

Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates

Zacks Investment Research

Gilead Sciences (GILD) came out with quarterly earnings of $2.03 per share, beating the Zacks Consensus Estimate of $1.89 per share. This compares to earnings of $1.81 per share a year ago.

Read full article arrow
News Thumbnail
4:39 PM | Thursday | May 7, 2026

Gilead Sciences Expects Loss This Year on Acquired R&D Expenses

WSJ

The biopharmaceutical company said it expects a 2026 adjusted loss of between $1.05 and 65 cents a share, compared with prior guidance of adjusted earnings between $8.45 and $8.85 a share.

Read full article arrow
News Thumbnail
4:05 PM | Thursday | May 7, 2026

Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Reuters

Gilead Sciences on Thursday posted a higher-than-expected first-quarter profit and raised its outlook for 2026 sales, but said ​it now expects a loss for the year due to ‌charges and financing costs related to recent acquisitions.

Read full article arrow
News Thumbnail